LogicBio Therapeutics, Inc. (LOGC)
Stock Price:
$7.61 USD
-0.20 (-2.56%)
Updated Jul 8, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
178.33M |
| Revenue (ttm) |
1.02M |
| Net Income (ttm) |
-41.89M |
| Shares Out |
23.43M |
| EPS (ttm) |
-1.84 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 8, 2020 |
| Last Price |
$7.61 |
| Previous Close |
$7.81 |
| Change ($) |
-0.20 |
| Change (%) |
-2.56% |
| Day's Open |
7.85 |
| Day's Range |
7.50 - 7.97 |
| Day's Volume |
30,219 |
| 52-Week Range |
3.05 - 14.00 |
More Stats
| Market Cap |
178.33M |
| Enterprise Value |
144.27M |
| Earnings Date (est) |
Aug 18, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
23.43M |
| Float |
7.40M |
| EPS (basic) |
-1.85 |
| EPS (diluted) |
-1.84 |
| FCF / Share |
-1.69 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
63,932 |
| Short Ratio |
1.33 |
| Short % of Float |
0.50% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
174.66 |
| PB Ratio |
5.78 |
| Revenue |
1.02M |
| Operating Income |
-42.27M |
| Net Income |
-41.89M |
| Free Cash Flow |
-39.22M |
| Net Cash |
34.06M |
| Net Cash / Share |
1.45 |
| Gross Margin |
n/a |
| Operating Margin |
-4,139.76% |
| Profit Margin |
-4,102.40% |
| FCF Margin |
-3,841.72% |
| ROA |
-42.14% |
| ROE |
-78.64% |
| ROIC |
-150.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$20.33*
(167.15% upside)
Low
17.0
Current: 7.61
High
24.0
Target: 20.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -41.04 | -17.94 | -5.85 | -3.40 |
| Net Income | -40.13 | -17.62 | -7.74 | -3.77 |
| Shares Outstanding | 22.60 | 5.80 | 1.40 | 0.85 |
| Earnings Per Share | -1.78 | -3.04 | -5.54 | -4.43 |
| Operating Cash Flow | -38.75 | -15.27 | -5.78 | -2.37 |
| Capital Expenditures | -1.42 | -0.58 | -0.04 | -0.23 |
| Free Cash Flow | -40.17 | -15.85 | -5.82 | -2.60 |
| Cash & Equivalents | 51.42 | 81.05 | 24.58 | 1.73 |
| Total Debt | 9.81 | - | - | - |
| Net Cash / Debt | 41.61 | 81.05 | 24.58 | 1.73 |
| Assets | 55.66 | 82.91 | 26.17 | 2.03 |
| Liabilities | 13.37 | 2.69 | 1.71 | 0.92 |
| Book Value | 42.29 | 80.23 | -8.60 | -3.25 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
LogicBio Therapeutics, Inc. |
| Country |
United States |
| Employees |
41 |
| CEO |
Frédéric Chéreau |
Stock Information
| Ticker Symbol |
LOGC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: LOGC |
| IPO Date |
October 19, 2018 |
Description
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop new genome editing candidate Lb-301 for the treatment of crigler-najjar syndrome. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.